AptarGroup (ATR) 47th Annual Raymond James Institutional Investor Conference summary

Company Overview, Strategic Positioning, and Financial Highlights

• Operates in about 20 countries, with Europe as the largest region, and generated $3.8 billion in 2025 revenue across pharma, beauty, and closures segments.

• Maintains leadership in drug and consumer product dosing, dispensing, and protection technologies, supported by a diversified portfolio and over 7,300 patents, with R&D spend at ~3% of sales, primarily focused on pharma innovation.

• Recognized as a sustainability and ESG leader, earning top industry accolades and enhancing customer value and talent attraction.

• Maintains a strong balance sheet with leverage at 1.38x EBITDA, among the lowest in its peer group, and disciplined capital allocation with two-thirds of capital reinvested in growth and one-third returned to shareholders.

• Operates in large, growing addressable markets, with pharma, beauty, and closures segments projected for long-term growth.

Technology, Innovation, and Intellectual Property

• Owns over 7,300 patents, with 62% related to pharma, and leverages shared technology platforms and proprietary drug delivery systems across segments.

• Innovation drives growth, with AI-assisted quality control, digital health analytics, and expanded service capabilities enhancing the value proposition.

• R&D spend is focused on pharma innovation, supporting a robust pipeline and repeat business.

• Expanded expertise includes human factors knowledge and digital health services, boosting customer engagement and device sales.

Market Opportunities and Growth Outlook

• Pharma packaging TAM is $165 billion (7% CAGR), beauty at $38 billion (4% CAGR), and closures at $7 billion (2% CAGR).

• Demonstrated ability to outpace market growth, with long-term revenue growth targets of 4%-7% overall and 7%-11% for pharma.

• Highly diversified portfolio across products and geographies, reducing reliance on any single area.

• Forward-looking statements emphasize continued innovation, pipeline expansion, and operational excellence.